The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Open accessAbstract
In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging-Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of Alzheimer's pathology. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the preclinical states of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, P-tau181 concentration is the most accurate indicator for differentiating AD from non-AD dementia.372,373”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [373]
In the citing paper
“Due to the lack of biomarkers, it is difficult to distinguish Alzheimer's disease from other dementias [6].”
From Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning (2023) · cites this paper as [6]
In the citing paper
“Recently, both European and American associations highlighted the importance of biomarkers in AD which is featured by amyloid-β (Aβ) plaques (A), pathological tau (T), and neurodegeneration (N) [6][7][8].”
From Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning (2023) · cites this paper as [6]
In the citing paper
“Current criteria for AD diagnosis require well-defined clinical phenotype and pathophysiological biomarkers consistent with AD pathology (Dubois et al., 2014).”
From Small nucleolar RNAs in plasma extracellular vesicles and their discriminatory power as diagnostic biomarkers of Alzheimer's disease (2021) · cites this paper as Dubois et al., 2014
In the citing paper
“AD has preclinical, prodromal, and dementia phases”
From Alzheimer’s disease drug development pipeline: 2021 (2021) · cites this paper as [20]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationCognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557
Self-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citation
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
“While differences remain, IWG 2016 and the NIA research framework are aligned on the key issue that the combination of an abnormal Ab and tau biomarker constitutes AD regardless of cognitive symptoms, and thus AD is a biologically defined entity throughout its continuum.”
InfluentialSelf-citationDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationLane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Metadata
- Authors
- Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M.-O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., & Cummings, J. L.
- Affiliations
- Inserm (FR)
- Vancouver Coastal Health (CA)
- University of British Columbia Hospital (CA)
- Sahlgrenska University Hospital (SE)
- University of Virginia (US)
- Douglas Mental Health University Institute (CA)
- Brigham and Women's Hospital (US)
- Washington University in St. Louis (US)
- Vita-Salute San Raffaele University (IT)
- National Hospital for Neurology and Neurosurgery (GB)
- University of Antwerp (BE)
- University of Geneva (CH)
- UCL Queen Square Institute of Neurology (GB)
- University of California San Diego (US)
- University of Kentucky (US)
- Karolinska University Hospital (SE)
- Centre Hospitalier Universitaire de Lille (FR)
- University of California, San Francisco (US)
- Centre Hospitalier Universitaire de Nice (FR)
- Austin Hospital (AU)
- Brown University (US)
- Centre Hospitalier Sainte-Anne (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Maastricht University Medical Centre (NL)
- University of Southern California (US)
- NewYork–Presbyterian Hospital (US)
- Vrije Universiteit Amsterdam (NL)
- Cleveland Clinic (US)
- Corresponding author
- Dubois, Bruno
- ORCID
- Dubois, Bruno
- Feldman, Howard H
- Jacova, Claudia
- Hampel, Harald
- Blennow, Kaj
- DeKosky, Steven T
- Gauthier, Serge
- Selkoe, Dennis
- Bateman, Randall
- Cappa, Stefano
- Crutch, Sebastian
- Engelborghs, Sebastiaan
- Frisoni, Giovanni B
- Fox, Nick C
- Galasko, Douglas
- Habert, Marie-Odile
- Jicha, Gregory A
- Nordberg, Agneta
- Pasquier, Florence
- Rabinovici, Gil
- Robert, Philippe
- Rowe, Christopher
- Salloway, Stephen
- Sarazin, Marie
- Epelbaum, Stéphane
- Vellas, Bruno
- Visser, Pieter J
- Schneider, Lon
- Stern, Yaakov
- Scheltens, Philip
- Cummings, Jeffrey L
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 13
- Issue
- 6
- Pages
- 614-629
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2116709840
- Cited by
- 3,321
- References
- 214
- Citations by year
- 2026: 138 · 2025: 197 · 2024: 240 · 2023: 270 · 2022: 302 · 2021: 361 · 2020: 361 · 2019: 310 · 2018: 308 · 2017: 297 · 2016: 263 · 2015: 218 · 2014: 43
- FWCI
- 208.97
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
- Economic and Social Research Council (ES/L001810/1)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, Research Diagnostic Criteria, NIA-AA criteria, clinical phenotype, biomarkers, atypical Alzheimer's disease, preclinical Alzheimer's disease, volumetric MRI, FDG-PET, disease staging, diagnostic framework
- MeSH terms
- Alzheimer Disease, Humans, International Cooperation, Phenotype, Societies, Medical, Biomarkers, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. https://app.cochat.ai/papers/10.1016/s1474-4422(14)70090-0
- The paper
- Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M.-O., Jicha, G. A., Nordberg, A., . . . Cummings, J. L. (2014). Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(14)70090-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.